TMCnet News
BioInformatics LLC projects market for CRISPR/Cas9 products to grow by 37% in the next 12 monthsThe $200 million market for CRISPR/Cas9 genome editing products is projected to grow by 37% in the next 12 months. The finding is contained in a new report, The Market for CRISPR/Cas9 Genome Editing Products, published by BioInformatics LLC, the premier research and advisory firm in the life science industry. "The speed at which this market is growing is unlike anything we've seen since the discovery of RNAi in the early 2000's," observed Robin Rothrock, PhD, Senior Science Advisor at BioInformatics. "The effectiveness, simplicity and versatility of the technology are driving rapid adoption." CRISPR/Cas9 - Clustered Regularly Interspaced Short Palindromic Repeats - is a foundational technology that is generating great excitement in the life science community. CRISPR/Cas9 enables scientsts to make specific changes in the DNA of humans, animals, and plants and can be applied to everything from agricultural biotechnology to developing treatments for disease. "The non-profit repository Addgene is currently the organization most scientists think of as their primary supplier of CRISPR/Cas9 products," says Rothrock. "But 74% of scientists currently using the technique have been using it for less than three years leaving little time to develop strong brand attachments." Indeed, among those scientists who say they will adopt the technique in the next 12 months, many say they plan to purchase from commercial suppliers, especially Agilent (News - Alert) Technologies, Sigma-Aldrich and Thermo Fisher. "There will be a steady movement away from homebrew methods toward the convenience and reliability of commercial solutions," predicts Rothrock. "Our survey of CRISPR/Cas9 users shows clearly that scientists are looking for higher throughput, faster time-to-results and more effective ways to validate results." For more information on the report, please visit gene2drug.com/reports. ABOUT BIOINFORMATICS LLC Now celebrating 20 years in business, BioInformatics LLC and its SDi division form the premier research and advisory firm serving the life science and analytical instrument industries. Offerings include assessing the size and attractiveness of scientific markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150528006088/en/ |
